Clinical trials: Advanced Gastric Cancer
Gastric Cancer
Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer: a Randomized Controlled Trial
The purpose of this study is to to investigate the feasibility and safety of fast-track surgery when combined with laparoscopic-assisted gastrectomy for advanced gastric cancer patients.
- Trial name
- FTSlapAG (NCT01955096)
- Testing
- fast-track surgery, conventional postoperative care
- Volunteers
- 61 people
- Sponsor
- Quan Wang
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06902545
- Testing
- zolbetuximab
- Where
- 15 sites in South Korea
- Volunteers
- 377 people
- Sponsor
- Astellas Pharma Korea, Inc.
Metastatic Gastric Cancer
Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer
The primary end-point of this study is to evaluate the objective response rates, and the secondary end-points are overall survival, progression-free survival and safety profile of low-dose RAD001 (everolimus) plus cisplatin and…
- Trial name
- NCT00632268
- Testing
- RAD001; Cisplatin; 5-FU; Leucovorin
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
Questionnaire Survey of the Advanced Training Program for Laparoscopic Radical Gastrectomy
This study aims to evaluate the outcomes of the advanced training program for laparoscopic radical gastrectomy (ATP-LRG). The research subjects are the trainees who participated in this training program.
- Trial name
- ATP-LRG-1 (NCT05219539)
- Where
- China
- Volunteers
- 1,355 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Cancer
Multiple Ascending Dose of BMS-911543
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum…
- Trial name
- NCT01236352
- Testing
- BMS-911543
- Where
- 5 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Locally Advanced Unresectable or Metastatic Gastric Cancer
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer…
- Trial name
- NCT07547787
- Where
- China
- Volunteers
- 610 people
- Sponsor
- Akeso
Second Line Treatment of Gastric Cancer
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs.
- Trial name
- NCT05669807
- Testing
- Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan
- Volunteers
- 184 people
- Sponsor
- Zhejiang Cancer Hospital
Stomach Cancer, Stomach Cancer Recurrent
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory stomach…
- Conditions
- Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer
- Trial name
- BAH250 (NCT06532799)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Gastric Cancer, Peritoneal Metastases
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
Data demonstrating the efficacy of PIPAC in patients with regionally advanced gastric cancer with positive peritoneal cytology and/or minimal peritoneal disease is limited due to the relatively recent development of this…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Chemotherapy Effect
- Trial name
- SPECTRA (NCT05318794)
- Testing
- Doxorubicin and Cisplatin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Gastric Cancer
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving higher doses may kill more tumor cells.
- Trial name
- NCT00002722
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Volunteers
- 135 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Gastric Cancer
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC).
- Trial name
- NCT00743964
- Testing
- Epirubicin, Cisplatin, capecitabine
- Where
- South Korea
- Volunteers
- 91 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achieving better prognostic…
- Trial name
- NCT06573307
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Chang-Ming Huang, Prof.
Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
This study evaluates the change of quality of life, treatment decision and utilization of health care depending on the use of palliative care in advanced cancer patients by a prospective cohort study.
- Conditions
- Stage IV Breast Cancer, Stage IV Pancreatic Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer
- Trial name
- NCT03222258
- Testing
- Early palliative care, Routine hospice care
- Where
- 15 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Seoul National University Hospital
Gastric Cancer
Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
- Trial name
- NCT04181333
- Testing
- TRASTUZUMAB BS
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Pfizer
Gastric Cancer
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer deaths in the world. In spite of the progresses made in the diagnosis and treatment of gastric cancer in the past decades, the prognosis is…
- Trial name
- NCT04086888
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University